GILEAD SCIENCES
65 QUAI GEORGES GORSE 92100
BOULOGNE BILLANCOURT
ILE DE FRANCE France
Gilead could potentially end HIV. But will it be able to?
The company’s twice-a-year PrEP medication was 100% effective in trials and hit the market last year.
Source: Pharma Voice Mar 20, 2026
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Source: Zacks Mar 19, 2026
A Look At Gilead Sciences (GILD) Valuation As Recent Returns Send Mixed Signals
What recent performance says about Gilead Sciences (GILD) With no single news headline setting the tone, Gilead Sciences (GILD) has still given investors plenty to think about, as the share price and fundamentals paint a mixed, data rich picture. Over the past month the stock shows a return of about a 9% decline, while the past 3 months reflect roughly a 16% gain and the 1 year total return sits near 35%. Longer term shareholders see very large gains, with total returns around 101% over 3...
Source: Simply Wall St. Mar 19, 2026
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $141.29, denoting a -2.15% move from the preceding trading day.
Source: Zacks Mar 18, 2026
3 Reasons to Avoid GILD and 1 Stock to Buy Instead
Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead Sciences has surged 127% to $145.23 per share. Its momentum hasn’t stopped as it’s also gained 27.8% in the last six months, beating the S&P by 26.8%.
Source: StockStory Mar 18, 2026
Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push
Gilead Sciences (NASDAQ:GILD) executives outlined the company’s approach to next-generation HIV medicines, ongoing commercialization efforts in liver disease, and a broad slate of oncology and inflammation programs during a discussion hosted by Leerink Partners analyst Daina Graybosch. HIV: Moving
Source: MarketBeat Mar 17, 2026
- Laboratory ceramic ware
- Zipper bags
- Packing containers of glass
- Laminated sheets of plastic
- Plastic caps for bottles
- Machines for testing physical properties
- Laboratory centrifuges
- Paper and paperboard labels
- Microscopes
- Furniture, of wood
- Glass ampoules
- Automatic data processing machines
- Computer keyboards
- Sterile syringes
- Photographic plates and film
- Paper for copying purposes
- Printed books
- Catalogs, brochures, and similar printed matter
- Writing pads
- Stationery articles of paper
- Self-adhesive paper
- Filters and filter media
- Laboratory glassware
- Filter funnels/separating funnels
- Materials of precious metal
- Manometers
- Drilling machines
- Laboratory ovens
- Balances of a sensitivity of 5 cg or better
- Water baths
- Laboratory glassware
- Metering or dispensing pumps
- Instruments and apparatus for physical or chemical analysis
- Chromatographs and electrophoresis instruments
- Microscope slides and cover glasses
- Culture media
- Biochemicals
- Reagents
- Analytical reagents
- Research chemicals
- Diagnostic reagents, based on antibody
- Genetic material
- Laboratory chemicals
- Reagents, adapted for laboratory or clinical uses
- Enzymes
- Antibodies
- Clinical laboratory reagents and diagnostic patient samples
- Antibodies for in vitro and diagnostic uses
- Diagnostic test kits, based on antibody
- Diagnostic or laboratory reagents
- Reagents and diagnostic reagents based on antibody
- Monoclonal antibodies
- Immunochemical reagents
- Diagnostic test kits and reagents
- Reagents based on mono or polyclonal antibody
- Diagnostic reagents
- Reagents and diagnostic reagents
- Reagents and diagnostic reagents, based on antibody
IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.
All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.